Hello McMagyar. Unfortunately, they did not report MMSE data and it was a secondary endpoint test only. They will probably report that at the November meeting.
They did two other tests for primary endpoints. One was called ADAS-Cog, which had the cognition improvement of 57% better than placebo. The other test they did was ADCS-ADL, which clearly failed, apparently because of the pandemic related questions.
Please allow me to rephrase my summary. The company expected the best response to be from the patients that had the P. gingivalis bacteria. And indeed these patients when given the HIGH dose, did better than the other patients that did NOT have the bacteria and the ones that got the placebo. In fact, from the start (baseline) they declined only about 43% as much as the placeboed patients, at the end (11months). These were the 'super responders'. They declined, but less than half as much as not getting anything at all. (actually 43%)
Now the question I always ask, is "How many of all the people with AD will be helped?". The answer is 37.6%. Of all the AD patients, 37.6% had the bacteria present. So, if you took 1000 people with AD and gave them 80mg COR388, 376 would perform the best, only declining 43% as much as the other 624. The 624 might be helped a little, but we cannot tell from the data the company PRed.
From what I remember of the Biogen data, this COR388 is better. COR388 works better (43% decline) and works on more people 37.6%. I would much rather try COR388 than the Biogen drug!
As a point of reference to say A2-73. If you recall the A2-73 super-responders did not decline at all, but actually improved. I also believe the A2-73 super responders will be 57%. These are the people with the wild type genes.
Hope this is clearer. All is in my humble opinion of course!
News 
Market Data 
Discover 
